Translation of "Vertriebsaufwendungen" in English

Selling Expenses came in at Euro 1.369 MM (1.088).

At the same time, net selling expenses did not increase and remained stable.

The Company has reclassified warranty expenses from Selling Expenses to Cost of Sales.

Selling Expenses came in at Euro 1.689m (1.433).

In 2018, selling expenses amounted to EUR 6.4 million (2017: EUR 4.8 million).

The increase of the selling expenses is mainly due to increasing advertising expenses in relation to seasonal marketing products.

Earnings in the third quarter were burdened by increased sales expenses and the accelerated expansion of expertise for new solution offerings.

Germany states that the loans were used exclusively to finance measures taken in the service provider sector and aimed at such things as optimising the customer tariff structure, adjusting sales expenditure and cutting current staff costs, the dual purpose being simply to keep the firm's ordinary business running and to reduce the need for liquidity during the rescue phase.

At the same time, the sales structures were strengthened and selling expenses increased by 13.6% to €36.7 (32.3) million.

Higher general and administrative expenses incurred in the prior-year period were mainly due to preparations for potential capital measures that were ultimately not conducted while selling expenses recognized in the prior-year period comprised essential costs related to the initiation and preparation of license agreements which have only been incurred to a lesser extent in the reporting period.

2014 Selling Expenses have been reduced by EUR 1,836 k (2013: EUR 14,457 k) and Cost of Sales increased by the same amounts.

In the second quarter of 2019, cost of sales amounted to EUR4.9 million (in Q2 2018, this item did not exist), selling expenses amounted to EUR3.2 million (Q2 2018: EUR1.5 million).

At the same time, the sales structures were strengthened and selling expenses increased by 13.6% to €36.7 (32.3) million.

Selling expenses have been reduced by kEURÂ 1,836 in 2014 (2013 kEURÂ 14,457) and Cost of Sales increased by the same amounts.

Efforts to strengthen the cost position were able to largely offset the continuing pressure on prices, the negative currency translation effects and investments in future growth through higher sales expenditures.

Splitting out selling expenses led to a change in the presentation of research and development expenses and general and administrative expenses for 2017, which were reduced by EUR 3.5 million and EUR 1.3 million, respectively.

Selling expenses rose by 4.1% to €196.8 (189.0) million, while administrative expenses increased by 2.1% to €76.4 (74.8) million.

Despite the increased selling and distribution expenses arising from the expansion of the Group's own retail business, EBITDA before special items rose by 5% to EUR 591 million (2013: EUR 565 million).

That is mainly due to higher selling expenses as a result of expanded sales capacities, intensified marketing activities and higher commissions for sales partners due to the successful business performance.

This change mainly stems from a decrease of selling expenses due to lower expenses for market research activities in the reporting period.

In the first quarter of 2019, selling expenses amounted to EUR 1.7 million (Q1 2018: EUR 0.8 million).

In comparison to the first nine months of 2014, sales expenses decreased by 7.9%, from EUR 7.6 million to EUR 7.0 million.

The increase mainly relates to an increase in selling expenses particularly in connection with the set-up of the supply chain for remimazolam.

Selling expenses have been reduced by kEUR1,836 in 2014 (2013 kEUR14,457) and Cost of Sales increased by the same amounts.

The EUR 1.2 million (10.1 percent) increase in sales costs in particular was due to a deliberate strategic personnel buildup.

To reflect the build-up of commercial structures for MOR208 in the U.S. initiated in July 2018, MorphoSys started presenting "selling expenses" as a separate line item on January 1, 2018.

Higher marketing and sales expenditure resulted particularly from the successful expansion of the US business and higher revenues from the sale of CENIT software via distribution partners such as SAP, IBM/FileNet and Dassault Systèmes.

Since the company at the same time managed to increase its international presence without raising its selling expenses, the operating result in the Professional Mobile Radio Systems segment saw a greater improvement than expected.